CAR-T Cell Therapy
CAR-T cell therapy is a cancer immunotherapy that uses a patient’s own T cells to recognize and attack certain cancer cells. It is used for selected blood cancers, including B-cell leukemia, lymphoma, and multiple myeloma, depending on diagnosis, previous treatment, eligibility, and approved indications.
How Does CAR-T Cell Therapy Work?
Treatment begins with apheresis, which collects T cells from the patient’s blood. In a specialized laboratory, the cells are genetically modified to produce chimeric antigen receptors (CARs), helping them recognize proteins on cancer cells. The modified cells are multiplied and returned through an intravenous infusion. Lymphodepleting chemotherapy is commonly given before infusion.
Who May Be Eligible?
CAR-T therapy may be considered for selected patients whose blood cancer has returned, progressed, or not responded adequately to previous treatment. Eligibility depends on cancer type, target antigen, treatment history, overall health, and other clinical factors. A hematologist or oncology specialist should assess suitability.
Benefits and Safety
CAR-T therapy can provide a targeted immune response and may produce durable remission in some eligible patients. However, it requires close monitoring. Potential complications include cytokine release syndrome (CRS), infections, low blood counts, and neurological problems such as ICANS.